Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Candidate Influenza Vaccine GSK1247446A- 2 different formulations · 1 trial · 1 indication
Titers are presented as geometric mean titers (GMTs). The 3 flu strains assessed were A/New Caledonia, A/New York and B/Malaysia. The reference seropositivity cut-off value was ≥ 1:10.
| Arm | Type | Description |
|---|---|---|
| GSK1247446A-AS03 Group | EXPERIMENTAL | Subjects aged 60 years or older at the time of the vaccination who received 1 dose of GSK1247446A vaccine adjuvanted with AS03. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm. |
| GSK1247446A Group | EXPERIMENTAL | Subjects aged 60 years or older at the time of the vaccination who received 1 dose of non-adjuvanted GSK1247446A vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm. |
| Fluarix Group | ACTIVE_COMPARATOR | Subjects aged 60 years or older at the time of the vaccination who received 1 dose of Fluarix vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm. |
| Name | Type | Description |
|---|---|---|
| Candidate Influenza Vaccine GSK1247446A - 2 different formulations | BIOLOGICAL | Single dose, Intramuscular injection |
| FluarixTM | BIOLOGICAL | Single dose, Intramuscular injection |
Inclusion criteria: * A male or female age 60 years or older at the time of the vaccination. * Subjects who the investigator believes can and will comply with the requirements of the protocol * Written informed consent obtained from the subject. * Free of an acute aggravation of the health status a...
Top 8 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE3 | mRNA Seasonal Flu vaccine, Flu/COVID-19 mRNA combination vaccine |
| Moderna, Inc. | MRNA | 2 | PHASE3 | mRNA-1018-H5, mRNA-1010, Fluarix Trivalent |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | CDTX | 1 | PHASE3 | CD388 |
| Traws Pharma, Inc. | TRAW | 2 | PHASE2 | TRX-100 |
| Sanofi SA Sponsored ADR | SNY | 4 | PHASE1 | H5N8 pandemic influenza vaccine (adjuvanted) |
| Hoffmann-La Roche | RHHBY | 2 | PHASE3 | Baloxavir Marboxil |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD4117, AZD5315 |
| Sinovac Biotech Ltd. | SVA | 1 | PHASE1 | Cell-based Trivalent Split Influenza Virus Vaccine, Egg-based Trivalent Split Influenza Virus Vaccine |
Candidate Influenza Vaccine GSK1247446A is an investigational vaccine being developed for the prevention of influenza. It is intended for use in older adults, with the completed Phase 2 study enrolling participants aged 60 years and older. It is not an approved product and remains in clinical development.
Candidate Influenza Vaccine GSK1247446A is being developed by GSK plc, which trades under the ticker GSK. GSK is the sponsor of the clinical program evaluating this influenza vaccine candidate.
Candidate Influenza Vaccine GSK1247446A is in Phase 2 development. One Phase 2 trial has been completed, and no active trials are currently listed for this candidate. It is an investigational vaccine and has not been approved for any indication.
Candidate Influenza Vaccine GSK1247446A has been studied in one completed Phase 2 trial, NCT00321373, titled Study to Evaluate an Influenza Vaccine Candidate. That trial enrolled 1,220 participants in Finland and Greece, was randomized and active-controlled, and included healthy volunteers aged 60 years and older.